Reducing Activities: company scaling back some business operations while continuing others
Stay Scaling Back
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease.
Reducing Activities: company scaling back some business operations while continuing others
Stay Scaling BackUCB is still bringing medicines to patients in Russia but we have reviewed the way in which we conduct our business there. Profits generated in Russia will be donated to NGOs to help the people of Ukraine. We have already stopped enrolling new patients and are not starting up any new sites or clinical trials in Russia. We are no longer undertaking marketing activities and are exploring other steps we can take to support the sanctions. Revenue decreased in 2024 vs 2023 by more than -10%.